Jodie A. Schildkraut

Dec 10, 2024 | publications.ersnet.org | Jodie A. Schildkraut |Niklas Köhler |Christoph Lange |Raquel Duarte

IntroductionTuberculosis (TB) continues to be one of the deadliest infectious diseases worldwide, with 10.6 million individuals developing the disease and ∼1.3 million deaths in 2022 [1]. The limitations of conventional diagnostic methods (e.g. sputum smear microscopy, PCR and culture), such as their slow turnaround times, lack of sensitivity in certain cohorts and technical challenges, have been well recognised [2, 3].